Objectives: To assess the level of agreement between digital rectal examination findings of two urologists and its effect on risk prediction using the digital rectal examination-based Rotterdam Prostate Cancer Risk Calculator. Methods: The study sample consisted of a prospective cohort of asymptomatic unscreened men with prostate-specific antigen ≤50.0 ng/mL and transrectal ultrasound volume ≤110 mL who underwent transrectal ultrasound-guided prostate biopsy. Both urologists' digital rectal examination findings were graded normal or abnormal (nodularity and/or induration), and volume classified as 25, 40 or 60 mL, according to the risk calculator algorithm. Interrater agreement analysis using Cohen's kappa (j) statistic was carried out to determine consistency of digital rectal examination outcome and volume assessment. Receiver operating characteristic curve analysis and calibration plots were constructed to determine the effect of interrater differences. Decision curve analysis was applied to evaluate the clinical usefulness of the model. Results: Of the 241 men included in the study, 41% (n = 98) had prostate cancer (81 were clinically significant, i.e. Gleason ≥3 + 4). There was substantial agreement in the digital rectal examination (abnormal/normal; j = 0.78; P < 0.001) and volume estimation (j = 0.79; P < 0.001). Receiver operating characteristic analyses showed good discrimination (0.75-0.78) and were comparable for both urologists. In the high-risk cohort, at a probability threshold of 25%, the risk calculator reduced the prostate biopsy rate by 9%, without missing cancers. Conclusions: Slight differences in digital rectal examination findings seem to have very limited impact on the performance of the Rotterdam Prostate Cancer Risk Calculator. Therefore, this can be considered a useful prostate biopsy outcome prediction tool.
Introduction
To reduce overdiagnosis and overtreatment, a prostate Bx should only be offered to men at increased risk of having a potentially life-threatening PCa. 1 The optimal algorithm remains a debatable issue in urology. 2 Even though the serum PSA test is the mainstay in the decision to carry out a Bx, the outcome of a DRE is also often considered. 1 However, to compensate for their intrinsic lack of specificity, a multivariate approach, taking into account other relevant pre-biopsy information is advised. 1 This can be done using socalled risk calculators, such as the RPCRC, based on biopsy data from the ERSPC section Rotterdam.
The ERSPC DRE-based risk calculator, which includes PSA, DRE outcome and DRE-assessed prostate volume as predictors, suitable for men facing initial biopsy, was developed to include information on prostate volume but to circumvent the need for imaging studies (e.g. TRUS or MRI), enabling easier implementation into the daily practice of both urologists and GPs. 4 Furthermore, although some men might benefit from additional characterization with MRI or biomarkers, using PSA and DRE as initial risk stratification can control healthcare costs.
Although the TRUS-based RPCRC has been externally validated in various patient populations with good results, the DRE-based RPCRC has not. 5 DRE has been shown to correlate with TRUS-assessed prostate volume, but it is a subjective test that requires external validation. [6] [7] [8] Therefore, we assessed the level of agreement between the DRE findings (both on abnormalities and estimation of prostate volume) of two urologists in men with a suspicion of PCa, and subsequently examined the potential effect on calculated risks when using the DRE-based RPCRC 3.
Methods

Study population
All men who were referred for Bx at the urology department of a university hospital in Portugal, between July 2014 and June 2015, were evaluated by two urologists, with >10 years of clinical experience, who had no previous contact with the patients nor their clinical records.
Methods
After a complete explanation of the procedure, all patients provided written consent for the data collection. Before the TRUS-guided Bx, two urologists (NPA and IB), blinded from each other's findings, carried out a DRE, with the patient in the left lateral decubitus position, to detect prostate induration/nodularity and to estimate prostate volume. Afterwards, prostate volume was assessed by TRUS (NPA), again blinded from DRE results, and patients were submitted to a 16-core TRUS-guided systematic biopsy under local anesthesia (NPA).
Symptoms, clinical staging and tPSA value were obtained from the patient's clinical file. According to the RPCRC 3 (DRE-based), only asymptomatic men with no previous prostate biopsy, with total PSA ≤50.0 ng/mL and a TRUS-measured prostate volume ≤110 mL at the time of biopsy were included in the prospective cohort. Urologist 1: r = 0.876; P < 0.001; urologist 2: r = 0.843; P < 0.001.
DRE findings of both physicians were classified as normal or abnormal. A DRE was considered abnormal if there was any induration and/or nodularity. Prostate volume was assessed by DRE, and recorded as <25 mL, 4-60 mL or >60 mL, according to the RPCRC algorithm. 3, 4 Patients were subsequently submitted to a 16-core TRUS-guided systematic biopsy under local anesthesia.
Statistical analysis
Statistically significant differences in men with and without PCa detected at biopsy were assessed using the Mann-Whitney U-test for continuous data, and the v 2 -test for categorical data. An interrater agreement for DRE examination, which included DRE outcome (abnormal/normal) and prostate volume assessment, between two urologists was estimated using j.
In addition, r was calculated to evaluate the association between DRE-assessed volume and TRUS-assessed volume. The diagnostic accuracy of the RPCRC for any-grade and HG (i.e. Gleason ≥3 + 4) PCa was quantified using ROC analysis. Calibration of the RPCRC for any-grade and HG PCa was explored graphically by the construction of validation plots for both urologists. In addition, we applied decision curve analysis to evaluate the potential clinical usefulness of making decisions based on the models, and to compare the DRE-based RPCRC with and without DRE-assessed prostate volume included in the model (i.e. comparing it with a strategy based on PSA and DRE outcome only).
9,10 Analyses were carried out using SPSS v20 (IBM Corporation, Armonk, NY, USA), and the R statistical package, version 3.2.2 (https://www.r-project.org/) was applied to develop calibration plots and decision curve analysis.
Statistical significance was set at P < 0.05 for all analyses.
Results
A total of 241 men were evaluated, with a median age of 66 years, a median PSA of 6.9 ng/mL and a median prostate volume of 40 mL (as evaluated by DRE) or 47 mL (as evaluated by TRUS; Table 1 ). PCa was diagnosed in 98 of 241 patients (41%), and 81 (34%) men had significant PCa defined as >T2b and/or Gleason ≥7. PCa patients were significantly older (median age 69 vs 65 years for non-PCa patients; P < 0.001), and had significantly smaller prostate glands (median TRUS-assessed prostate volume 39 vs 53 mL; P < 0.001). Median tPSA was significantly higher for men with PCa than without PCa (7.4 vs 6.6 ng/mL; P = 0.005). Considering the DRE examination (abnormal/normal), there was substantial agreement between the two urologists (j = 0.783; P < 0.001). A similar outcome was found when comparing DRE-based volume estimations (j = 0.790; P < 0.001).
DRE-assessed volume (<25 mL, 40-60 mL or >60 mL) was significantly correlated with TRUS-assessed volume for both urologists (urologist 1: r = 0.876; P < 0.001; urologist 2: r = 0.843; P < 0.001; Table 2 ).
ROC analyses showed good discrimination in predicting both any-grade cancer (AUC 0.77 and 0.78) and HG PCa (AUC 0.75 and 0.76), and were highly comparable between urologists (Table 3) . Figures 1 and 2 show DRE-based RPCRC calibration plots for both urologists and for PCa and HG PCa, respectively. DRE-based RPCRC showed adequate calibration, and only slight underestimations between predicted and observed probabilities of PCa for both urologists. DRE-based RPCRC for PCa had better calibration than DRE-based RPCRC for HG PCa. Figure 3 shows the decision curves for DRE-based RPCRC, with and without prostate volume included in the algorithm for predicting any-grade PCa (Fig. 3a) and HG PCa (Fig. 3b) . The use of the DRE-based RPCRC model with prostate volume information has a higher NB than the PSA and DRE normal/abnormal model for both urologists. Taking into account prostate volume assessment with DRE, improved NB was obtained for any-grade PCa, but not for HG PCa.
As part of assessing the usefulness of the DRE volumebased RPCRC, we analyzed whether using this risk calculator to identify patients with and without cancer would help reduce unnecessary biopsies. Tables 4 and 5 show the values of each urologist per model at a given threshold probability for biopsy carried out/saved, prostate cancer detected/missed, NB and NR in avoidable biopsies per 100 patients for anygrade PCa and HG PCa, respectively. For illustration, a threshold of 25% for any PCa could be used, meaning, respectively, four men should undergo a biopsy to find any PCa. For HG PCa, a lower threshold might be used, for example 5%, allowing 20 men to be biopsied to find one HG PCa. Urologist 1 would have saved 43.6% (n = 105) biopsies and would have missed 23.5% (n = 23) of any PCa when using the DRE-based RPCRC, whereas the numbers for a model without information on volume would be less: 35.3% (n = 85) biopsies saved and 22.4% (n = 22) PCa missed, respectively. To observe the difference between the DREassessed prostate volume-based RPCRC and RPCRC without prostate volume, both urologist results were pooled together. Weighing the benefits (avoided biopsies) versus the harms (missed diagnosis) for both urologists, at the given threshold probability of 25%, DRE-assessed prostate volume-based RPCRC lowers the biopsy rate for nine out of 100 patients, without missing any PCa when compared with the RPCRC without prostate volume. For HG PCa, the negative NR implies that the best clinical outcome would be achieved by biopsy in all men irrespective of the risk calculator results.
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Only for a threshold of ≥20% was the NB for risk calculator higher than for carrying out a biopsy in all.
Discussion
This is the first study to externally validate the DRE version of the RPCRC, in which there is no need to carry out invasive imaging to assess prostate volume, as volume assessment is based on a DRE estimate. The primary outcome of the present study was the effect of the interobserver variability of a subjective predictor, such as DRE and DRE-assessed volume. To the best of our knowledge, this is the first cohort that used DRE-assessed volume classes (<25 mL, 40-60 mL or >60 mL, according to the RPCRC algorithm) and not recoded values from TRUS examinations. 3 Even though there were differences in performance between the two urologists, this had little impact on the performance of the DRE-based RPCRC for PCa (AUC 0.77 vs 0.78) and for HG PCa (AUC 0.75 vs 0.76).
An abnormal DRE is a putative indication for Bx, and carrying out a DRE is useful in a pre-biopsy setting.
1 A metaanalysis of DRE as a screening test for PCa has shown a sensitivity of 53.2% and positive predictive value of 17.8%. 12 This was confirmed in an analysis of the DRE-based RPCRC, clearly showing the added value of combining DRE with other clinical information. 4 Furthermore, the DRE-assessed prostate volumes were highly correlated with TRUS-assessed volumes in both urologists. Even though prostate volume can vary according to age and race, and the DRE is not an objective test, it has been shown that when it is carried out in an organized method, there is little interobserver variability. [13] [14] [15] Furthermore, it has been shown that there is little variation between consultants and trainees, and the DRE learning curve is short. 16 The TRUS-based RPCRC has been thoroughly validated and compared with other risk calculators in several cohorts with good performance. [17] [18] [19] [20] Estimation of prostate volume by TRUS is, however, invasive, time-consuming and has added costs, even if carried out by the attending urologist during the clinical visit. Furthermore, when risk assessment is applied in the first line of care, which is recommendable to decrease unnecessary referrals, assessment of prostate volume by TRUS, similar to a MRI and/or more complex biomarker information, warrants an external referral for a radiologist or urologist. This can be circumvented by using a DRE-based multivariate assessment tool for initial risk stratification. 1 In a recent study, in which 122 consecutive men received a multiparametric MRI scan and subsequent MRI-TRUS fusion targeted biopsy in case of suspicious lesions (Prostate Imaging Reporting and Data System 3) after a negative TRUS-guided random biopsy, it was concluded that using the RPCRC for risk stratification can economize half the number of multiparametric MRI. 21 Future research is, however, necessary to confirm the applicability of the DRE-based RPCRC in a GP setting.
Using decision curve analysis, the DRE-based RPCRC showed better NB gains relative to the RPCRC without prostate volume for prediction of any-grade PCa. It also showed that by using the RPCRC, the number of unnecessary biopsies in the patients without PCa can be reduced with no increase in the number of patients with PCa left unscreened.
Using the risk calculator for selective detection of HG PCa showed no additional benefit. This might be due to the fact that the model slightly underestimated HG PCa risk, reducing the NB. 22 It must be noted that in the current study, the prevalence for overall and HG PCa was high; irrespective of the outcome of a risk model, 34% HG PCa was present. The added benefit of multivariate risk stratification can be expected to be higher in a screening population, where the prevalence of HG PCa is lower and hence the potential to save unnecessary biopsies is higher.
Currently, no single multivariate tool has proven its superiority, among the many available alternatives, 1,2,5,23 although one meta-analysis showed that the RPCRC performed very well. 5 Further studies, preferably with head-to-head comparisons, are required to further clarify this issue. Until then, using the DRE-based RPCRC or another specific risk calculator remains a personal choice of the clinician. For added convenience, the DRE-based RPCRC is available online (http:// www.prostatecancer-riskcalculator.com/seven-prostate-cancerrisk-calculators), and also as a smartphone app, for both Android and iOS devices, where in addition to individual probabilities, recommendations on interpretation are provided.
The present study had some limitations. First, our study cohort was relatively small, comprised of men referred to our academic center from GPs and other hospitals, on the basis of a clinical suspicion, because screening is not common in our region, which could explain the elevated proportion of men with clinically significant PCa, and also limit the statistical significance and the generalization of our findings related to calibration and NB. The DRE evaluation, which was carried out without access to previous medical information, was implemented by experienced clinicians. Younger trainees and GPs might obtain different results, as it has been shown that there can be a learning curve for DRE. 24 Hence, further validation might be necessary for these particular settings.
In summary, this is the first external validation of the DRE-based version of the RPCRC, a PSA-and DRE-based multivariable risk assessment tool, which uses DRE to assess both prostate abnormalities as well as volume. Even though there were slight differences in DRE outcomes between the two urologists, this had little impact on the performance of the RPCRC. In our high-risk cohort, the DRE-based RPCRC showed good discrimination, but NB was limited. A DREbased RPCRC can be considered as a cost-effective, quick to use, broadly deployable tool to aid in identifying men at risk of having (clinically significant) PCa, especially in a screening setting.
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